MPV17L

Across TCGA pan-cancer cohorts, MPV17L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MPV17L data layer compared with 28 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MPV17L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MPV17L expression acts as an unfavorable survival marker.

LUSC, COAD, and UCEC are the cancer types where MPV17L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.178	0.776	.003	30	view →
COAD	OS	Median	II,III,IV	0.001	0.860	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	All	0.115	0.555	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MPV17L–LUSC (OS)

Open the LUSC breakdown →